Trial Profile
Peg-interferon-alfa to achieve HBsAg loss in multi-drug resistance HBV under long-term viral suppression with tenofovir DF +/- lamivudine salvage therapy
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Lamivudine; Tenofovir disoproxil fumarate
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms TRUST-109
- 01 Oct 2013 New trial record